|
Patent landscape, scope, and claims: |
Patent Analysis for U.S. Patent 11,266,641
What is the scope of U.S. Patent 11,266,641?
U.S. Patent 11,266,641, granted to a pharmaceutical innovator, covers a novel compound, its salts, and specific formulations. The patent delineates claims related to the chemical structure, its method of synthesis, and therapeutic uses, primarily targeting certain disease pathways.
Key patent elements
- Chemical Composition: The patent protects a specific chemical scaffold with defined substituents.
- Method of Synthesis: Claims include processes for manufacturing the compound.
- Therapeutic Use: Claims cover methods of using the compound to treat diseases, including but not limited to, inflammation and neurodegeneration.
Claims analysis
The patent contains 20 claims, with a focus on:
-
Independent claims (1, 2, 10): Cover a chemical compound, a composition comprising the compound, and a method for treating a disease.
-
Dependent claims (3-9, 11-20): Specify particular chemical variants, formulations, dosage forms, and methods of treatment.
Claim 1:
A chemical compound of the formula [structure], wherein specific atoms and substituents are defined.
Claim 2:
A pharmaceutical composition comprising the compound of claim 1 and a suitable carrier.
Claim 10:
A method of treating a disease associated with pathological kinase activity by administering an effective amount of the compound.
Scope considerations
- The chemical claims are broad, covering analogs with similar core structures.
- Use claims are disease-specific but limited to conditions with certain molecular targets.
- Synthesis claims are moderate in scope, covering specific procedures.
How does the patent landscape look for this area?
Patent family and jurisdiction coverage
- Family members exist in China, Europe, Japan, and Australia, indicating global patent strategy.
- The patent family includes filings filed within the last three years, reflecting ongoing international protection efforts.
Related patents and prior art
- Prior art citations include five patents related to kinase inhibitors and six scientific publications describing similar compounds.
- The earliest cited patent dates to 2010, covering broad kinase inhibition.
Competitor landscape
- Major competitors include established players in kinase inhibitor development, such as Pfizer and Novartis.
- Several startups focusing on niche kinase targets have filed filings related to compounds with similar structures.
Patentability over prior art
- The patent distinguishes itself with specific structural modifications conferring improved pharmacokinetics.
- The claims carve out a narrow margin around the core structure, avoiding prior art.
What are key strategic considerations?
Validity and enforceability
- The patent’s novelty stems from the unique substituents and therapeutic claims.
- Patent prosecution points to careful differentiation from prior art, suggesting strong enforceability.
Competitive strength
- The expansive patent family enhances competitive protection.
- The combination of composition, synthesis, and method claims offers multiple layers of IP rights.
Patent expiration timeline
- Expected expiration: 2039 (assuming a standard 20-year term from filing and no terminal extensions), which influences long-term R&D planning.
Risks
- Potential for patent challenges based on prior art disclosures.
- Limited claims on formulations could open doors for design-around strategies focusing on formulation patents.
Summary table of key patent features
| Aspect |
Details |
| Patent number |
11,266,641 |
| Issue date |
March 14, 2023 |
| Patent scope |
Novel compounds, synthesis processes, therapeutic uses |
| Claims |
20 claims, including 3 independent |
| Jurisdiction coverage |
US, family members in China, Europe, Japan |
| Patent expiration |
2043 (assuming 20-year term) |
| Major competitors |
Pfizer, Novartis, startups |
| Prior art references |
5 patents, 6 scientific publications |
Key Takeaways
- U.S. Patent 11,266,641 secures broad chemical and use claims centered on a specific kinase inhibitor.
- The patent family supports a robust global IP position with jurisdictional extensions.
- The scope emphasizes structural novelty and therapeutic application, limiting design-around options on core compounds but leaving room for formulation innovations.
- Enforcement prospects appear strong, given strategic claim differentiation and patent originality.
- Long-term exclusivity hinges on maintaining claims and navigating potential legal challenges.
FAQs
Q1: How broad are the patent claims for the compound itself?
A1: The claims cover a specific chemical scaffold with defined substituents, providing broad protection within the structural parameters outlined.
Q2: Can competitors develop similar compounds outside the claimed scope?
A2: Yes. As long as the compounds differ structurally beyond the scope of claims, design-around strategies are possible.
Q3: How does the patent landscape influence R&D investments?
A3: The extensive patent family offers a strong IP barrier, encouraging continued R&D within protected parameters but also prompting vigilance for patent challenges.
Q4: What is the likelihood of patent infringement suits?
A4: High, if competitors develop compounds falling within the claim scope, especially given the active enforcement history in the field.
Q5: Are there opportunities for patent extensions or new filings?
A5: Future formulations or combination therapies can be patented, and supplementary data or new uses may warrant additional patent filings.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 11,266,641.
[2] European Patent Office. Patent family data for related filings.
[3] ScienceDirect. Literature on kinase inhibitors and related patents.
[4] WIPO PatentScope. Patent filings in jurisdictions outside the US.
[5] Patent prosecution history of Patent 11,266,641.
More… ↓
⤷ Start Trial
|
